Literature DB >> 32997518

PI-RADS Version 2.1: A Critical Review, From the AJR Special Series on Radiology Reporting and Data Systems.

Andrei S Purysko1, Ronaldo H Baroni2, Francesco Giganti3,4, Daniel Costa5, Raphaële Renard-Penna6, Chan Kyo Kim7, Steven S Raman8.   

Abstract

PI-RADS version 2.1 updates the technical parameters for multiparametric MRI (mpMRI) of the prostate and revises the imaging interpretation criteria while maintaining the framework introduced in version 2. These changes have been considered an improvement, although some issues remain unresolved, and new issues have emerged. Areas for improvement discussed in this review include the need for more detailed mpMRI protocols with optimization for 1.5-T and 3-T systems; lack of validation of revised transition zone interpretation criteria and need for clarifications of the revised DWI and dynamic contrast-enhanced imaging criteria and central zone (CZ) assessment; the need for systematic evaluation and reporting of background changes in signal intensity in the prostate that can negatively affect cancer detection; creation of a new category for lesions that do not fit into the PI-RADS assessment categories (i.e., PI-RADS M category); inclusion of quantitative parameters beyond size to evaluate lesion aggressiveness; adjustments to the structured report template, including standardized assessment of the risk of extraprostatic extension; development of parameters for image quality and performance control; and suggestions for expansion of the system to other indications (e.g., active surveillance and recurrence).

Entities:  

Keywords:  MRI; PI-RADS; prostate cancer

Mesh:

Year:  2020        PMID: 32997518     DOI: 10.2214/AJR.20.24495

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  7 in total

1.  [Can progression of prostate cancer be reliably diagnosed using serial magnetic resonance imaging during active surveillance?]

Authors:  Analena Elisa Handke; Markus Graefen; Tim Ullrich; Andreas Wibmer; Boris Alexander Hadaschik; Francesco Giganti; Lars Schimmöller; Jan Philipp Radtke
Journal:  Urologe A       Date:  2021-10-07       Impact factor: 0.639

2.  Validating the screening criteria for bone metastases in treatment-naïve unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases.

Authors:  Erik Rud; Daniyal Noor; Kristina Flor Galtung; Fredrik Ottosson; Maciej Jacewicz; Eduard Baco; Peter Mæhre Lauritzen
Journal:  Eur Radiol       Date:  2022-08-08       Impact factor: 7.034

Review 3.  A narrative review of MRI acquisition for MR-guided-radiotherapy in prostate cancer.

Authors:  Jing Yuan; Darren M C Poon; Gladys Lo; Oi Lei Wong; Kin Yin Cheung; Siu Ki Yu
Journal:  Quant Imaging Med Surg       Date:  2022-02

4.  PI-RADS and Likert scales for structured reporting in multiparametric MR imaging of the prostate.

Authors:  Shivang Desai; Daniel N Costa
Journal:  Br J Radiol       Date:  2021-09-29       Impact factor: 3.039

5.  Comparison of diagnostic performance and inter-reader agreement between PI-RADS v2.1 and PI-RADS v2: systematic review and meta-analysis.

Authors:  Chau Hung Lee; Balamurugan Vellayappan; Cher Heng Tan
Journal:  Br J Radiol       Date:  2021-09-14       Impact factor: 3.039

6.  Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer.

Authors:  Alp Tuna Beksac; Parita Ratnani; Zachary Dovey; Sneha Parekh; Ugo Falagario; Reza Roshandel; Stanislaw Sobotka; Deepshikha Kewlani; Avery Davis; Rachel Weil; Hafis Bashorun; Ivan Jambor; Sara Lewis; Kenneth Haines; Ashutosh K Tewari
Journal:  Cancer Rep (Hoboken)       Date:  2021-12-20

7.  Quantib Prostate Compared to an Expert Radiologist for the Diagnosis of Prostate Cancer on mpMRI: A Single-Center Preliminary Study.

Authors:  Eliodoro Faiella; Daniele Vertulli; Francesco Esperto; Ermanno Cordelli; Paolo Soda; Rosa Maria Muraca; Lorenzo Paolo Moramarco; Rosario Francesco Grasso; Bruno Beomonte Zobel; Domiziana Santucci
Journal:  Tomography       Date:  2022-08-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.